健康な成人参加者における経口投与ABBV-1042の体内動態と有害事象を評価する研究
第Ⅰ相二重盲検プラセボ対照初回ヒト試験:健常被験者におけるABBV-1042単回漸増投与の安全性、忍容性、および薬物動態の評価
This study will assess the adverse events, tolerability, and how oral ascending doses of ABBV-1042 moves through the body of healthy adult participants.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Illinois
-
Grayslake、Illinois、アメリカ、60030
- Acpru /Id# 279405
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
- Body weight ˃ 45 kg at the time of screening and upon initial confinement.
- A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG
Exclusion Criteria:
- History of suicidal ideation within one year prior to study treatment administration and/or history of suicidal behavior or non-suicidal self-injury within two years prior to study treatment administration as evidenced by any "yes" answer to questions on the Columbia-Suicide Severity Rating Scale (C-SSRS) at the screening visit or upon initial confinement.
- Current or past history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine (including diabetes mellitus, thyroid disorders), malignancy, hematological, immunological, neurological, or psychiatric disease that, , in the opinion of the investigator, could compromise either participant safety or the results of the trial.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:トリプル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:ABBV-1042 or Placebo-Group 1
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
|
実験的:ABBV-1042 or Placebo-Group 2
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
|
実験的:ABBV-1042 or Placebo-Group 3
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
|
実験的:ABBV-1042 or Placebo-Group 4
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
|
実験的:ABBV-1042 or Placebo-Group 5
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
|
実験的:ABBV-1042 or Placebo-Group 6
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants Experiencing Adverse Events
時間枠:Up to approximately 32 days
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to approximately 32 days
|
|
Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements
時間枠:Up to approximately 3 days
|
Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed. |
Up to approximately 3 days
|
|
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
時間枠:Up to approximately 3 days
|
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior. |
Up to approximately 3 days
|
|
Number of Participants with Abnormal Change in Physical Examinations
時間枠:Up to approximately 3 days
|
Number of participants with abnormal change in physical examinations in areas like cardiovascular, respiratory, and neurological systems will be assessed. |
Up to approximately 3 days
|
|
Number of Participants with Change from Baseline in Electrocardiogram (ECG)
時間枠:Up to approximately 3 days
|
12-lead resting ECG will be recorded. |
Up to approximately 3 days
|
|
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed
時間枠:Up to approximately 3 days
|
Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed. |
Up to approximately 3 days
|
|
Maximum Plasma Concentration (Cmax) of ABBV-1042
時間枠:Up to approximately 3 days
|
Cmax of ABBV-1042 |
Up to approximately 3 days
|
|
Time to Cmax (Tmax) of ABBV-1042
時間枠:Up to approximately 3 days
|
Tmax of ABBV-1042 |
Up to approximately 3 days
|
|
Apparent terminal phase elimination constant (β) of ABBV-1042
時間枠:Up to approximately 3 days
|
β of ABBV-1042 |
Up to approximately 3 days
|
|
Terminal Phase Elimination Half-Life (t1/2) of ABBV-1042
時間枠:Up to approximately 3 days
|
t1/2 of ABBV-1042 |
Up to approximately 3 days
|
|
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCt) of ABBV-1042
時間枠:Up to approximately 3 days
|
AUCt of ABBV-1042 |
Up to approximately 3 days
|
|
Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of ABBV-1042
時間枠:Up to approximately 3 days
|
AUCinf of ABBV-1042 |
Up to approximately 3 days
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:ABBVIE INC.、AbbVie
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- M25-818
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。